37 studies found for:    " May 30, 2012":" June 29, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" May 30, 2012":" June 29, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Enrolling by invitation Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
Condition: HIV Infections
Intervention: Drug: No Investigational Product
2 Completed An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: darunavir (PREZISTA);   Drug: etravirine (INTELENCE);   Drug: ritonavir;   Drug: Other antiretroviral medications
3 Recruiting Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
Condition: HIV Infections
Interventions: Drug: Dapivirine;   Drug: Placebo
4 Enrolling by invitation HIV Disclosure and Medication Adherence, a Pilot Study
Condition: HIV Infection
Intervention:
5 Active, not recruiting Metabolic Abnormalities in HIV-infected Persons
Conditions: Lipodystrophy;   HIV Infection
Interventions: Drug: Metformin;   Drug: Pioglitazone
6 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
7 Active, not recruiting A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Condition: HIV Infections
Interventions: Drug: Doravirine;   Drug: Efavirenz;   Drug: TRUVADA®
8 Active, not recruiting MARCH Renal Substudy
Conditions: Proteinuria;   HIV
Interventions: Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors;   Drug: Arm 2 boosted protease inhibitors and maraviroc;   Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
9 Completed
Has Results
Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
Condition: HIV
Intervention: Drug: Etravirine pharmacokinetics in breast milk and plasma
10 Recruiting Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
Conditions: HIV;   AIDS;   Substance Abuse;   Inpatient
Interventions: Behavioral: Patient Navigation (PN) Group;   Behavioral: Patient Navigator Plus Contingency Management (PN+CM) Group
11 Recruiting Clinical Trial to Reduce Drinking in Women With HIV
Condition: HIV Infection
Interventions: Drug: Naltrexone;   Drug: Placebo
12 Active, not recruiting Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX
Condition: HIV Infection
Interventions: Behavioral: Text reminders, counseling, and link coordination;   Behavioral: Standard of care - control arm
13 Active, not recruiting Linking Infectious and Narcology Care in Russia
Conditions: HIV Infection;   Drug Use
Intervention: Behavioral: LINC Case Management
14 Unknown  Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women
Conditions: HIV Infection;   Pregnancy
Intervention:
15 Enrolling by invitation Addressing Proven Factors in HIV Prevention for Latino Youth
Conditions: HIV;   Sexually Transmitted Infections
Interventions: Behavioral: audio-CD parent education;   Behavioral: health and success parent and school
16 Completed Evaluation of the Bioequivalence of a Combined Formulated Tablet
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg;   Drug: Dolutegravir 50 mg;   Drug: abacavir 600 mg/lamivudine 300 mg
17 Active, not recruiting HIV Posterior Cheek Enlargement
Condition: HIV Posterior Cheek Enlargement
Intervention: Biological: Botulinum toxin A
18 Completed Home-Based Versus Partner-Friendly Clinic Testing to Enhance Male Partner HIV-1 Testing During Pregnancy
Conditions: Male Partner;   HIV Counseling and Testing;   Home Based;   Pregnancy
Intervention: Other: HIV counseling and testing
19 Completed Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Condition: HIV-1 Infection
Interventions: Drug: Vacc-C5/GM-CSF;   Drug: Vacc-C5/Alhydrogel
20 Active, not recruiting MARCH Central Nervous System Substudy
Condition: HIV-1 Infection
Interventions: Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors;   Drug: Arm 2 Maraviroc and Protease Inhibitors;   Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Indicates status has not been verified in more than two years